Pericardial effusion after streptokinase for acute myocardial infarction: an echocardiographic 1-year follow-up study.
Since the reported incidence of pericardial effusion following thrombolysis is highly variable, we have evaluated 80 consecutive patients with first acute myocardial infarction treated with streptokinase. Two-dimensional echocardiographic studies were performed on days 1, 2, 3, and 7, at 3 and 6 weeks, and 3, 6, and 12 months following acute myocardial infarction. Throughout the study, pericardial effusion was found in 7 of 80 (8.75%) patients, being small in 5 patients, moderate in 1, and large in 1 patient. No clinical, angiographic, or echocardiographic variable was associated with pericardial effusion formation. The incidence of pericardial effusion found in our study is almost three times lower than in other echocardiographic studies on pericardial effusion in thrombolysed patients. Whether this differences results from the beneficial effects of streptokinase is not clear.
Otasević
P
P
Cardiovascular Research Center, Dedinje Cardiovascular Institute, Belgrade, Yugoslavia.
Nesković
A N
AN
Bojić
M
M
Popović
A D
AD
D001783:Blood Flow Velocity; D002306:Cardiac Volume; D017023:Coronary Angiography; D015150:Echocardiography, Doppler; D004562:Electrocardiography; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction; D009203:Myocardial Infarction / Q000188:drug therapy*; D010490:Pericardial Effusion / Q000139:chemically induced* / Q000000981:diagnostic imaging; D011446:Prospective Studies; D013300:Streptokinase / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D013318:Stroke Volume; D015912:Thrombolytic Therapy / Q000009:adverse effects*
D005343:Fibrinolytic Agents; D013300:Streptokinase